Evolus, Inc. reported second quarter 2026 financial results with total net revenues of $84.1 million, a 21% increase year-over-year. The company achieved positive Adjusted EBITDA of $4.7 million for the third consecutive quarter, marking a $12.6 million improvement over the prior year period. Evolus raised its full-year 2026 net revenue guidance to between $330 million and $337 million and narrowed non-GAAP operating expense guidance to between $212 million and $216 million. The company also announced an exclusive U.S. licensing agreement with IBSA for Profhilo, a skin quality injectable expected to generate peak annual revenue exceeding $100 million upon commercialization in 2030. Additionally, Evolus expanded its Estyme franchise into Canada, Australia, and New Zealand. The company operates in the aesthetic injectables industry, developing and marketing neurotoxins and hyaluronic acid gels.

Evolus, Inc. entered into an amendment to its License, Supply and Distribution Agreement with Symatese Aesthetics S.A.S., expanding exclusive commercialization rights for the Estyme® injectable hyaluronic acid gel portfolio to Canada, Australia, and New Zealand. Evolus Europe must pay €920,000 in upfront signing fees plus up to €1.38 million upon obtaining regulatory approvals. Symatese retains responsibility for development and regulatory activities, with commercialization expected in 2028 under a 15-year initial term. This expansion completes Evolus' strategy to offer its neurotoxin and dermal filler portfolio across all international markets where it currently operates. Evolus, Inc. is a global performance beauty company that develops and distributes aesthetic injectable products.

Evolus, Inc. entered into a License, Supply and Distribution Agreement with IBSA Institut Biochimique SA on July 7, 2026, granting the Company exclusive rights to develop, commercialize, and distribute the injectable hyaluronic acid product Profhilo in the United States. The Company will fund all U.S. development, clinical, and regulatory activities to obtain FDA approval, and will purchase the product from IBSA under a transfer-price model following approval. The Agreement is for an initial term of 15 years from the first FDA approval, with no upfront or milestone payments required. Evolus, Inc. operates in the aesthetics and dermatological fields as a medical aesthetics company.